Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.8
4.4
Journals
Cancers
Special Issues
Contemporary Management for Gallbladder Cancer: From Diagnosis to Treatment (2nd...
cancers-logo
Submit to Special Issue Submit Abstract to Special Issue Review for Cancers Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Contemporary Management for Gallbladder Cancer: From Diagnosis to Treatment (2nd Edition)

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 30 June 2026 | Viewed by 2876

Special Issue Editor

Dr. Hiromichi Ito

E-Mail Website
Guest Editor
Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan
Interests: biliary cancer; liver cancer; pancreatic cancer; liquid biopsy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is the second edition of a previous issue on the topic of “Contemporary Management for Gallbladder Cancer: From Diagnosis to Treatment” (https://www.mdpi.com/journal/cancers/special_issues/7P5759X2MR).

Gallbladder cancer (GBCA) is a rare but aggressive disease with a propensity for early invasion of the adjacent organs and dissemination to lymph nodes and peritoneal surfaces. As patients with GBCA often remain asymptomatic until the advanced stage, it has historically been considered an incurable disease with dismal prognosis, and the clinical attitude towards GBCA has been characterized by pessimism in the past. In recent decades, however, chemotherapy for biliary cancer has evolved, and more effective regimens are more commonly used in the management of GBCA. Furthermore, along with recent increased use of computed tomography or abdominal ultrasound in general practice, the number of incidentally discovered patients with early stage GBCA has been increasing. Thus, in this Special Issue, we call for papers on the contemporary management of patients with GBCA and its outcomes. The scope includes modern multidisciplinary approaches for advanced GBCA, strategies for early GBCA, and other translational research for novel diagnostic/therapeutic strategies.

Dr. Hiromichi Ito
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gallbladder cancer
  • radical cholecystectomy
  • adjuvant chemotherapy
  • neoadjuvant therapy
  • incidental gallbladder cancer
  • multidisciplinary management
  • preoperative staging

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 900 KB  
Article
Actionable Genomic Alterations and Survival in Gallbladder Cancer: A Documented Stage- and Treatment-Matched Real-World Global Analysis
by Zeeshan Solangi, Katherin Zambrano-Vera, Laura Haas, Antonio J. Arciniegas, Zina Agha, Ghulam Shah, Ahmed Abbasi, Werner Kristjanpoller, Olga Kozyreva, Fernando Rotellar and Eduardo A. Vega
Cancers 2026, 18(9), 1452; https://doi.org/10.3390/cancers18091452 - 1 May 2026
Viewed by 601
Abstract
Background: GBC is an aggressive biliary tract malignancy with limited survival. Although actionable genomic alterations (AGAs) are increasingly recognized in GBC, their prognostic association in real-world practice remains incompletely defined because genomic status is often confounded by stage at presentation and treatment selection. [...] Read more.
Background: GBC is an aggressive biliary tract malignancy with limited survival. Although actionable genomic alterations (AGAs) are increasingly recognized in GBC, their prognostic association in real-world practice remains incompletely defined because genomic status is often confounded by stage at presentation and treatment selection. We evaluated the association between documented AGA status and overall survival (OS) using a tiered matching strategy to account for major clinical confounders. Methods: Using the TriNetX Global Collaborative Network, we identified adults with GBC and stratified them into patients with at least one documented AGA in KRAS, TP53, ERBB2, IDH1, FGFR1, PIK3CA, or ARID1A, and a comparison cohort with no documented AGA (representing a real-world population of untested and wild-type patients). Two 1:1 propensity score-matched models were constructed: Model 1 matched for age, sex, and race/ethnicity; Model 2 additionally matched for metastatic disease, surgical resection, and chemotherapy history. Outcomes were evaluated using risk analysis and Kaplan–Meier survival methods. Results: A marked disparity in genomic documentation was observed before matching, with unknown race recorded in 51.0% of the comparison cohort versus 3.7% of the documented AGA cohort. In the demographic-matched analysis (Model 1), the documented AGA cohort had higher mortality (52.8% vs. 42.5%, p < 0.001) and shorter median OS (684 vs. 948 days; HR 1.23, p = 0.006). In the primary stage- and treatment-matched analysis (Model 2), mortality remained higher in the documented AGA cohort (56.2% vs. 43.0%), corresponding to an absolute risk difference of 13.2% (p < 0.001). Median OS was numerically shorter in the documented AGA cohort (750 vs. 784 days), although the proportional hazards assumption was violated, supporting interpretation based primarily on absolute risk measures. In exploratory subgroup analyses, KRAS alterations were associated with worse survival, whereas the TP53 subgroup was limited by small sample size. Conclusions: In this real-world matched analysis, the presence of documented AGAs in GBC were associated with higher mortality even after matching for major demographic, stage-related, and treatment-related variables. These findings support the prognostic relevance of genomic status in GBC and underscore the need to address disparities in access to genomic documentation and testing. Full article
(This article belongs to the Special Issue Contemporary Management for Gallbladder Cancer: From Diagnosis to Treatment (2nd Edition))
►▼ Show Figures

Figure 1

Review

Jump to: Research

13 pages, 905 KB  
Review
Surgical Management of Locally Advanced and Metastatic Gallbladder Cancer
by Mitchell Breitenbach, Paul Burchard, Veer Kothari and Darren Carpizo
Cancers 2025, 17(24), 3952; https://doi.org/10.3390/cancers17243952 - 11 Dec 2025
Viewed by 1598
Abstract
Advances in systemic therapy for gastrointestinal malignancies have opened the door for surgical resection of tumors previously deemed unresectable. Of these tumors, gallbladder cancer has a particularly poor prognosis due to the aggressive nature of the disease. The preferred systemic therapy regimen for [...] Read more.
Advances in systemic therapy for gastrointestinal malignancies have opened the door for surgical resection of tumors previously deemed unresectable. Of these tumors, gallbladder cancer has a particularly poor prognosis due to the aggressive nature of the disease. The preferred systemic therapy regimen for gallbladder cancer has progressed from single-agent chemotherapy to multi-agent therapy including immune checkpoint inhibitors, with additional targeted therapies currently under investigation. These advancements have provided patients with historically unresectable tumors with a bridge to surgical resection and a hope of extended survival or cure. Surgical options for locally advanced tumors have expanded, and experienced centers perform a variety of operations to achieve resection with negative margins, including extended liver resection, bile duct resection, vascular reconstruction, and adjacent organ resection. There is also growing evidence that patients with Stage IV disease may benefit from resection of their primary tumors and metastases. This review outlines the current treatment practices for patients with locally invasive and metastatic gallbladder cancer as well as emerging treatment options. Full article
(This article belongs to the Special Issue Contemporary Management for Gallbladder Cancer: From Diagnosis to Treatment (2nd Edition))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop